A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells

Ibrutinib, a BTK inhibitor, is currently used to treat various hematological malignancies. We evaluated whether ibrutinib treatment during development of murine bone marrow-derived dendritic cells (DCs) modulates their maturation and activation. Ibrutinib treatment increased the proportion of CD11c(...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Natarajan, Gayathri, Oghumu, Steve, Terrazas, Cesar, Varikuti, Sanjay, Byrd, John C., Satoskar, Abhay R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2016
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4938315/
https://ncbi.nlm.nih.gov/pubmed/27471620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1151592
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi